Background: The management of osteoporosis requires drug treatment and changes in lifestyle. Adherence to medication does not exceed 50% at one year. Changes in lifestyle are rarely explored. Therapeutic requires a relay to continue the follow-up over several years Objectives: To improve the follow-up of the patient, we have created cooperation between the attending physician and the pharmacy pharmacist initiated by the patient himself Methods: We proposed a therapeutic patient education for patients treated for osteoporosis to participate in two half-day ETP sessions a year apart. Educational objectives are: The treatment of osteoporosis requires at least 5 years of treatment, and must be associated with the absorption of three dairy products per day, maintaining physical activity and preventing falls. Each patient participating in a therapeutic education session receives a follow-up notebook containing six doctor questionnaires and six pharmacist questionnaires. The patient remains the owner of the notebook. We were able to study the results of the 2-year questionnaires for 72 patients included in 2013 and 2014. Results: 53/72 patients continue their treatment at 2 years. 4 patients died, 1 had an atypical fracture of the femoral shaft, 6 stopped treatment due to dental treatment, 3 had contraindications to any anti-osteoporotic treatment, 1 decided to discontinue treatment due to d Multiple Sclerosis, 11 decided to leave the program. 3 patients were lost to follow-up, ie 14/72 patients of whom we no longer have any news. Of the 53 patients who continued treatment, 24 sent back a doctor and pharmacist questionnaire to 2 years. 4 doctors and 2 pharmacists refused to complete the questionnaires. The study of pharmacist questionnaires received at 2 years shows that 83% of patients continue to consume 3 dairy products per day compared to 73% at 6 months, 65% maintained physical activity, 17% improved it, 9% decreased. The ground balance was satisfactory for 78% of patients compared with 71% at 6 months. 71% never forget their treatment, compared with 69% at 6 months. 8% wanted to stop their treatment, stable figure compared to questionnaires received at 6 months. All patients knew what their treatment was for at one year and 96% met the conditions for taking the medication. 69% do not forget it at two years against 86% at one year, thanks to the intervention of the pharmacist. Only 6% wanted to stop the treatment at two years due to side effects, 17% to 1 year, but did not stop after consultation with the doctor and/or pharmacist. During the two-year follow-up, all patients were phone called at least once by a secretary, mostly several times. The notebook is driven by the patient himself, many oh them report to the nurse that it give them an active role which afoord them to continue the treatment Conclusions: 58% of the patients enrolled continue treatment at two years, 15% have stopped the treatment as a side effect. An active role given to the patient and a collaboration between physicians and pharmacists thus promote adherence to treatment and also changes in Background: Patient-reported outcomes (PROs) have evolved into an essential element in managing rheumatoid arthritis (RA), working in concert with physicianbased tools to assess disease activity and health-related quality of life [1] . Objectives: A study was conducted to determine whether an online educational intervention could effectively address a knowledge gap and an underlying educational need in applying data from patient registries including PROs in the management of patients with RA. Methods: An online educational intervention focusing on advances in RA patient registries was developed and made available online. The intervention consisted of a 30-minute video-based roundtable discussion between 3 experts in treatment of RA. The intended audience was rheumatologists who treat patients with RA. The educational impact was assessed by comparing participants' responses to 4 identical paired pre-and post-assessment questions. Data representing a statistical sampling of the overall learner population was collected from 5/29/2015 through 8/13/2015. Statistical analysis comprised a paired (within-physician) 2-tailed t-test comparing mean pre-intervention and post-intervention scores, McNemar's χ2 statistic for measuring changes in responses to individual. Cramer's V determined the overall effect of the intervention. Results: Analysis of pre-versus post-activity responses by rheumatologists (n=36) demonstrated a significant improvement (P<0.05) in overall knowledge with a robust effect size (V =0.339). This activity resulted in increased knowledge surrounding several specific areas of RA management, such as drug safety, alternative means of collecting PRO data, and issues surrounding pregnancy in women with RA. The absolute percentage increases in correct individual responses to these topics (all P<0.05 except where noted), included:
• 33% increase (36% vs. 69%) in rheumatologists who recognized the results from pooled registries in Europe -11 registries from 9 countries -regarding the safety of tumor necrosis factor-alpha inhibitor therapy, • 28% increase (36% vs 64%) in rheumatologists who recognized that biosensorbased devices can provide passive data regarding patient outcomes, • 14% increase (47% vs 61%, P=.237) in rheumatologists who identified the connected CORRONA-OTIS registries that provide information on patients with RA who become pregnant, • 62% increase (19% vs 81%) in rheumatologists who identified that patient registry data can be used to support a risk mitigation strategy for prescribing a specific DMARD in patients who may become pregnant during therapy. Conclusions: An online educational intervention was associated with significant improvement in knowledge levels of rheumatologists in several important aspects of RA management, including interpretation of data from patient registries and adverse effect profiles of approved therapies. Future directions for education include additional reinforcement regarding the roles for PROs in patient management, and assessing the impact of improved rheumatologists' knowledge on care delivery and patient outcomes. Background: Systemic lupus erythematosus (SLE) is a complex yet low prevalence disease. Without a community of lupus specialists to establish consensus and guide best practices, rheumatologists have limited opportunities to develop skills and maintain competence in SLE care. Objectives: The objectives of this initiative were to 1) create an independent community of physicians interested in the pathogenesis, diagnosis, and management of patients with SLE and related conditions; 2) share insights and practical guidance for implementing evidence-based care; 3) develop needs-driven contin-uing medical education (CME) relevant to different levels of clinical expertise; 4) promote collaboration models with publishers to create space for dialogue and community building; and 5) involve patient advocacy groups to steer physician education and incorporate the patient voice into educational activities. Methods: The Lupus Academy (http://lupus-academy.org) was established in 2011 as an independent CME initiative led by a Steering Committee of international experts in SLE.
THU0584 FIVE YEARS OF EXPERIENCE WITH THE LUPUS ACADEMY: AN EFFECTIVE MODEL FOR BUILDING A ROBUST COMMUNITY OF PRACTICE FOR GEOGRAPHICALLY DIVERSE LEARNERS
[1] Educational activities are designed around unmet clinical needs identified by the Steering Committee, learner survey data, and feedback from patient advocacy groups (including Lupus Europe). Results: As of February 2017, the Lupus Academy has grown to a global community of >2,500 committed learners with an interest in SLE. The Steering Committee has guided the development and delivery of 5 2.5-day annual meetings; 4 1-day regional meetings; a meeting toolkit for learner-advocates to host meetings in their home regions; and 3 e-learning courses, with 2 additional courses in production. The 5th Annual Meeting of the Lupus Academy (6-8 May 2016) hosted 101 attendees from Europe, North and South America, and Asia. Learners reported that the learning objectives of the meeting were met (Figure) . An assessment of educational effectiveness demonstrated improvements in clinical knowledge and competence (Moore's Outcomes Levels 3/4) as a result of meeting participation: 67% of learners reported a commitment to implementing changes in clinical practice, 11% reported that the educational content reinforced their current practice, and 20% reported a willingness to modify their current practice with additional training. The most recent regional meeting, the Lupus Academy Middle East Summit Conference (9-10 December 2016), hosted 153 attendees from 13 countries representing diverse specialities: rheumatology (53%), internal medicine (13%), nephrology (11%), clinical immunology (5%), and other (18%). The majority of learners agreed or strongly agreed that the meeting provided an effective platform for the discussion of new ideas in SLE (96%) and challenged the current thinking around lupus care (96%).
Conclusions:
The Lupus Academy serves as an effective model for building a consortium-led, evidence-based educational resource and community of practice for rheumatologists, other physicians with an interest in SLE, and patient advocacy groups.
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